546 related articles for article (PubMed ID: 31522467)
1. Association between response to rituximab and antibody-mediated rejection in ABO-incompatible living kidney transplantation.
Maenosono R; Unagami K; Kakuta Y; Furusawa M; Okumi M; Azuma H; Ishida H; Tanabe K
Int J Urol; 2019 Dec; 26(12):1114-1120. PubMed ID: 31522467
[TBL] [Abstract][Full Text] [Related]
2. ABO-incompatible pediatric kidney transplantation without antibody removal.
Kawamura T; Hamasaki Y; Takahashi Y; Hashimoto J; Kubota M; Muramatu M; Itabashi Y; Hyodo Y; Ohashi Y; Aikawa A; Sakai K; Shishido S
Pediatr Nephrol; 2020 Jan; 35(1):95-102. PubMed ID: 31673829
[TBL] [Abstract][Full Text] [Related]
3. Histological Analysis in ABO-Compatible and ABO-Incompatible Kidney Transplantation by Performance of 3- and 12-Month Protocol Biopsies.
Masutani K; Tsuchimoto A; Kurihara K; Okabe Y; Kitada H; Okumi M; Tanabe K; Nakamura M; Kitazono T; Tsuruya K;
Transplantation; 2017 Jun; 101(6):1416-1422. PubMed ID: 27391195
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of blood group antibodies in ABO-incompatible living-donor kidney transplantation.
Sugiyama K; Hyodo Y; Aikawa A
Int J Urol; 2015 Oct; 22(10):931-6. PubMed ID: 26108258
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the prevalence of systemic de novo thrombotic microangiopathy after ABO-incompatible kidney transplantation and the associated risk factors.
Tasaki M; Saito K; Nakagawa Y; Imai N; Ito Y; Yoshida Y; Ikeda M; Ishikawa S; Narita I; Takahashi K; Tomita Y
Int J Urol; 2019 Dec; 26(12):1128-1137. PubMed ID: 31587389
[TBL] [Abstract][Full Text] [Related]
6. Results of a multicenter prospective clinical study in Japan for evaluating efficacy and safety of desensitization protocol based on rituximab in ABO-incompatible kidney transplantation.
Takahashi K; Saito K; Takahara S; Fuchinoue S; Yagisawa T; Aikawa A; Watarai Y; Yoshimura N; Tanabe K; Morozumi K; Shimazu M;
Clin Exp Nephrol; 2017 Aug; 21(4):705-713. PubMed ID: 27534951
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of ABO-incompatible kidney transplant with rituximab and double-filtration plasmapheresis.
Han S; Hwang E; Park S; Park U; Kim H; Cho W
Exp Clin Transplant; 2014 Oct; 12(5):401-4. PubMed ID: 25299367
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of 2 Doses of Rituximab on B-Cell and Antidonor Antibody and Outcomes of ABO-Incompatible Living-Donor Pediatric Kidney Transplant.
Hamasaki Y; Aikawa A; Itabashi Y; Muramatsu M; Hyoudou Y; Shinoda K; Takahashi Y; Sakurabayashi K; Mizutani T; Oguchi H; Kawamura T; Sakai K; Shishido S
Exp Clin Transplant; 2019 Jan; 17(Suppl 1):105-109. PubMed ID: 30777532
[TBL] [Abstract][Full Text] [Related]
9. Single fixed low-dose rituximab as induction therapy suppresses de novo donor-specific anti-HLA antibody production in ABO compatible living kidney transplant recipients.
Tomita Y; Iwadoh K; Ogawa Y; Miki K; Kato Y; Kai K; Sannomiya A; Koyama I; Kitajima K; Nakajima I; Fuchinoue S
PLoS One; 2019; 14(10):e0224203. PubMed ID: 31644555
[TBL] [Abstract][Full Text] [Related]
10. ABO-incompatible living donor kidney transplantation without post-transplant therapeutic plasma exchange.
Yabu JM; Fontaine MJ
J Clin Apher; 2015 Dec; 30(6):340-6. PubMed ID: 25739580
[TBL] [Abstract][Full Text] [Related]
11. Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis.
Sawada T; Fuchinoue S; Teraoka S
Transplantation; 2002 Nov; 74(9):1207-10. PubMed ID: 12451255
[TBL] [Abstract][Full Text] [Related]
12. Three-year outcomes following 1420 ABO-incompatible living-donor kidney transplants performed after ABO antibody reduction: results from 101 centers.
Opelz G; Morath C; Süsal C; Tran TH; Zeier M; Döhler B
Transplantation; 2015 Feb; 99(2):400-4. PubMed ID: 25050471
[TBL] [Abstract][Full Text] [Related]
13. Outcomes Following ABO-Incompatible Kidney Transplantation Performed After Desensitization by Nonantigen-Specific Immunoadsorption.
Becker LE; Siebert D; Süsal C; Opelz G; Leo A; Waldherr R; Macher-Goeppinger S; Schemmer P; Schaefer SM; Klein K; Beimler J; Zeier M; Schwenger V; Morath C
Transplantation; 2015 Nov; 99(11):2364-71. PubMed ID: 25989497
[TBL] [Abstract][Full Text] [Related]
14. Outcome of ABO-Incompatible Living Donor Renal Transplantations: A Single-Center Experience From Eastern India.
Ray DS; Thukral S
Transplant Proc; 2016 Oct; 48(8):2622-2628. PubMed ID: 27788792
[TBL] [Abstract][Full Text] [Related]
15. Desensitization with the Use of an Antibody Removal-Free Protocol in ABO-Incompatible Kidney Transplant Recipients with a Low Anti-A/B Antibody Titer.
Nanmoku K; Shinzato T; Kubo T; Shimizu T; Kimura T; Yagisawa T
Transplant Proc; 2018 May; 50(4):982-986. PubMed ID: 29731097
[TBL] [Abstract][Full Text] [Related]
16. Postoperative rebound of antiblood type antibodies and antibody-mediated rejection after ABO-incompatible living-related kidney transplantation.
Ishida H; Kondo T; Shimizu T; Nozaki T; Tanabe K
Transpl Int; 2015 Mar; 28(3):286-96. PubMed ID: 25363583
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of rituximab dosage for ABO-incompatible living-donor kidney transplantation.
Nakao T; Ushigome H; Kawai K; Nakamura T; Harada S; Koshino K; Suzuki T; Ito T; Nobori S; Yoshimura N
Transplant Proc; 2015 Apr; 47(3):644-8. PubMed ID: 25891703
[TBL] [Abstract][Full Text] [Related]
18. Late-onset neutropenia and acute rejection in ABO-incompatible kidney transplant recipients receiving rituximab and mycophenolate mofetil.
Kabei K; Uchida J; Iwai T; Yamasaki T; Kuwabara N; Naganuma T; Kumada N; Nakatani T
Transpl Immunol; 2014 Aug; 31(2):92-7. PubMed ID: 24932811
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic apheresis in ABO-incompatible kidney and liver transplantation: A single-center experience of 50 patients.
Pandey P; Setya D; Sinha V; Bhatt A; Devra A; Chaudhary A; Ranjan S; Srivastava R; Kumar P; Singh MK
Ther Apher Dial; 2021 Feb; 25(1):103-117. PubMed ID: 32266793
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of high-dose mizoribine in ABO-incompatible kidney transplantation using anti-CD20 and anti-CD25 antibody without splenectomy treatment.
Yoshimura N; Ushigome H; Matsuyama M; Nobori S; Suzuki T; Sakai K; Okajima H; Okamoto M
Transplant Proc; 2012 Jan; 44(1):140-3. PubMed ID: 22310599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
